Decreased expression of c-myc oncoprotein by peripheral blood mononuclear cells in thalassaemia patients receiving desferrioxamine

European Journal of Haematology

Volumn 60, Issue 1, 1998, Pages 21-27

  Kyriakou, D ^a   Eliopoulos, A G ^b   Papadakis, A ^a   Alexandrakis, M ^a   Eliopoulos, G D ^a,c  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Beta thalassaemia; c myc; Desferioxamine

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; ONCOPROTEIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CELL STRAIN HL 60; CELL STRAIN K 562; CHILD; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; THALASSEMIA MAJOR;

EID: 0031973694     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb00992.x     Document Type: Article

References (38)

1. IGUCHI-ARIGA SM, ITANI T, KIJI Y, ARIGA H. Possible function of the c-myc product: promotion of the cellular DNA replication. EMBO J 1987: 6: 2365-2372.
2. KARN J, WATSON JV, LOWE A, VEDECKIS W. Regulation of cell cycle duration by c-myc levels. Oncogene 1989: 4: 773-787.
3. PENN LJZ, LAUFER EM, LAND H. C-myc: evidence for multiple regulatory functions. Semin Cancer Biol 1990: 1: 69-80.
4. KATO GJ, DANG CV. Function of the c-myc oncoprotein. FASEB J 1992: 6: 3065-3072.
5. COLE MD. The myc oncogene: its role in transformation and differentiation. Ann Rev Genet 1986: 20: 361-384.
6. EVAN GI, WYLLIE AH, GILBERT CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992: 69: 119-128.
7. ELIOPOULOS AG, KERR DJ, SPANDIDOS DA. The effect of doxorubicin, daunorubicin and 4′-epidoxorubicin on the exogenous c-myc promoter in mouse erythroleukemia cells. Anticancer Res 1991: 11: 2153-2158.
8. ELIOPOULOS AG, KERR DJ, MAURER HR, HILGARD P, SPANDIDOS DA. Induction of the c-myc but not the c-Hras promoter by platinum compounds. Biochem Pharmacol 1995:50: 33-38.
9. LACHMAN HM, HATTON K, SKOULTSI AI, SCHILDKRAUT CL. C-myc levels in the cell cycle changes in mouse erythroleukaemia cells following inducer treatment. Proc Natl Acad Sci (USA) 1985: 82: 5323-5327.
10. COPPOLA JA, COLE MD. Constitutive c-myc oncogene expression blocks mouse erythroleukemia cell differentiation but not commitment. Nature (Lond) 1986: 320: 760-763.
11. ELIOPOULOS AG, SPANDIDOS DA. Changes in FOS/JUN binding activity on a negative regulatory element of c-myc during differentiation of mouse erythroleukemic cells. Int J Oncol 1993: 2: 883-888.
12. AMATI B, DALTON S, BROOKS M, LITTLEWOOD TD, EVAN GI, LAND H. Transcriptional activation by human c-myc oncoprotein in yeast requires interaction with max. Nature (Lond) 1992: 359: 423-426.
13. AMATI B, BROOKS MW, LEVY N, LITTLEWOOD TD, EVAN GI, LAND H. Oncogenic activity of the c-myc protein requires dimerization with max. Cell 1993: 72: 233-245.
14. BRITTENHAM GM. Disorders of iron metabilism: iron deficiency and overload. In: HOFFMAN R, et al. (eds) Hematology - basic principles and practice. New York: Churchill Livingstone, 1991: 327.
15. SOFRONIADOU K, DROSSOU M, FOUDOULAKI L, KONSTANTOPOULOS K, KYRIAKOU D, ZERVAS J. Acute bone marrow aplasia associated with intravenous administration of desferrioxamine. Drug Saf 1990: 5: 152-153.
16. VOSKARIDOU E, KONSTANTOPOULOS K, KYRIAKOU D, LOUKOPOULOS D. Desferrioxamine treatment during early pregnancy. Haematologica 1993: 78: 183-184.
17. HOFFBRAND AV. Prospects for oral iron chelation therapy. J Lab Clin Med 1994: 123: 492-494.
18. HOFFBRAND AV, GENESHAGURU K, HOOTON JWL, TATTERSALL MHN. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 1976: 33: 517-526.
19. TOMOYASU S, NAKAMATI T, SUZUKI K, TSURUOKA N. Growth inhibition and promotion of differentiation induction in cultured leukemia cell lines by desferrioxamine. Acta Haematol Jpn 1987: 50: 568-574.
20. POLSON RJ, JENKINS R, LOMBARD M, et al. Mechanisms of inhibition of mononuclear cell activation by the iron chelating agent desferrioxamine. Immunology 1990: 71: 176-181.
21. FUKUCHI K, TOMOYASU S, TSURUOKA N, GOMI K. Iron deprivation induced apoptosis in HL60 cells. FEBS Lett 1994: 350: 139-142.
22. HILETI D, PANAGIOTIDIS P, HOFFBRAND AV. Iron chelators induce apoptosis in proliferating cells. Br J Haematol 1995: 89: 181-187.
23. RIAZ-UL-HAG, WERELEY JP, CHITAMBAR R. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol 1995: 23: 428-432.
24. NOCKA KH, PELLUS LM. Cell cycle specific effects of desferrioxamine on human and murine haemopoetic progenitor cells. Cancer Res 1988: 48: 3571-3575.
25. DACIE JV, LEWIS SM. Blood cytochemistry and supplementary techniques. In: Practical Haematology, 6th edn. Churchill Livingstone, 1984: 84-113.
26. KYRIAKOU D, ELIOPOULOS AG, ALEXANDRAKIS M, KALOKYRI I, ELIOPOULOS GD. Increased expression of c-myc p67 oncoprotein in patients with myelodysplastic syndromes in transformation to acute leukaemia. Haematologia 1996: 28: 1-7.
27. ELIOPOULOS AG, KERR DJ, HEROD J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 1995: 11: 1217-1228.
28. MCGAHON AJ, MARTIN SJ, BISSONNETTE RP, et al. The end of the (cell) line; methods for the study of apoptosis in vitro. In: WILSON L, MATSUDAIRA P (eds) Methods in cell biology, Vol. 46. Academic Press, 1995: 153-183.
29. JACOBS A. Low molecular weight intracellular iron compartments. Blood 1977: 50: 433-439.
30. CAZZOLA M, BERGAMASCHI G, DEZZA L, AROSIO P. Manipulations of cellular iron metabolism for normal and malignant cell proliferation: achievments and prospects. Blood 1990: 75: 1903-1919.
31. PHILIPPE C, FOUQUERAY B, PEREZ J, BAUD L. Upregulation of tumour necrosis factor-α receptors on monocytes by desferrioxamine. Clin Exp Immunol 1992: 87: 499-503.
32. PHILIPPE C, ROUXLOMBARD P, FOUUQERAY B, PEREZ J, DAYER J, BAUD L. Membrane expression of human blood monocytes - regulation by desferrioxamine. Immunology 1993: 80: 300-305.
33. ARBISER JL, ARBISER ZK, MAJZOUB JA. Effects of hydroxyurea and cyclic adenosine monophosphate protein kinase A on the expression of human choriogonadotrophin alpha subunit and c-myc genes in choriocarcinoma. J Endocrinol Invest 1993: 16: 849-856.
34. ARBISER JL, ARBISER ZK, MAJZOUB JA. Differential regulation of choriocarcinoma gene expression by DNA synthesis inhibitors. Endocr J 1993: 40: 263-268.
35. PATTANAPANYASAT K, WEBSTER HK, TONGTAWE P, KONGHAROEN P, HIDER RC. Effect of orally active hydroxypyridone iron chelators on human lymphocyte function. Br J Haematol 1992: 82: 13-19.
36. GALERANI M, CICOGNANI I, RICCI A, MARTINELLI L, DALL ARA G, FERRARI R, FAGLIONI M. Immunohistochemical pattern in heterozygote beta thalassaemic subjects. Riv Eur Sci Med Farmacol 1990: 12: 191-195.
37. LOMBARDI G, MATERA R, MINERVINI MM, et al. Serum levels of cytokins and soluble antigens in polytransfused patients with beta-thalassaemia major: relationship to immune status. Haematologica 1994: 79: 406-412.
38. GASCON P, ZOUMBOS NC, YOUNG NS. Immunologic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med 1984: 100: 173-177.